AI Article Synopsis
- Hereditary hemorrhagic telangiectasia (HHT) is a genetic condition that causes blood vessel abnormalities leading to nosebleeds and other serious health issues, with anti-angiogenic medications like bevacizumab and thalidomide being used off-label for treatment.
- A study involving 69 HHT patients treated with bevacizumab and 67 with thalidomide reported various adverse events (AEs), with bevacizumab showing a higher incidence in females and thalidomide's side effects being more frequent among patients with specific gene variants.
- Common AEs included joint pains and headaches for bevacizumab, while thalidomide commonly caused peripheral neuropathy and drowsiness
Article Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT) is a multisystemic inherited vascular dysplasia that leads to nosebleeds and visceral arteriovenous malformations (AVMs). Anti-angiogenic drugs thalidomide and bevacizumab have been increasingly used off-label with variable results. The HHT working group within the ERN for Rare Multisystemic Vascular Diseases (VASCERN), developed a questionnaire-based retrospective capture of adverse events (AEs) classified using the Common Terminology Criteria for Adverse Events.
Results: Sixty-nine HHT patients received bevacizumab, 37 (50.6%) for high output cardiac failure/hepatic AVMs, and 32 (49.4%) for bleeding; the 69 patients received bevacizumab for a mean of 11 months for a total of 63.8 person/years treatment. 67 received thalidomide, all for epistaxis and/or gastrointestinal bleeding; they received thalidomide for a mean of 13.4 months/patient for a total of 75 person/years treatment. AEs were reported in 58 patients, 33 with bevacizumab, 37 with thalidomide. 32 grade 1-3 AEs related to bevacizumab were reported with an average incidence rate of 50 per 100 person-years. 34 grade 1-3 AEs related to thalidomide were reported with an average incidence rate of 45.3 per 100 person-years. Bevacizumab AEs were more common in females (27 AEs in 46 women) than males (6 in 23, p < 0.001). Thalidomide AEs occurred at more similar rates in males (25 AEs in 41 men, 60.9%) and females (12 in 26 (46.2%), but were more common in ENG patients (17 in 17) than in ACVRL1 (14 in 34, p < 0.0001). For bevacizumab, the most common reports were of joint pains (7/69, 10%), headache (3/69, 4.4%) and proteinuria (2/69, 3%), and for thalidomide, peripheral neuropathy (12/67, 18%); drowsiness (8/67, 12%); and dizziness (6/67, 9%). Fatal adverse events were more common in males (p = 0.009), and in patients with ENG pathogenic variants (p = 0.012). One fatal AE was possibly related to bevacizumab (average incidence rate: 1.5 per 100 person-years); 3 fatal AEs were possibly related to thalidomide (average incidence rate: 4 per 100 person-years).
Conclusions: With potential increase in use of Bevacizumab and Thalidomide in HHT patients, data presented support appropriate weighing of the toxicities which can arise in HHT settings and the practice recommendations for their prevention and management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360670 | PMC |
| http://dx.doi.org/10.1186/s13023-018-0982-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Angiogenesis inhibitors effects on overall survival and progression-free survival in newly diagnosed primary glioblastoma multiforme: a meta-analysis of twelve randomized clinical trials.
J Neurooncol
December 2024
Department of Epidemiology and Biostatistics, School of Health, Reproductive Health and Population Research Center, Gonabad University of Medical Sciences, Gonabad, Iran.
Background: Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. Typically treated with initial surgical resection, and chemoradiotherapy, despite current treatments, patients typically survive only 12-14 months, necessitating new therapeutic approaches. Our meta-analysis evaluates combining antiangiogenic medications with chemoradiotherapy versus using chemoradiotherapy alone in treating newly diagnosed GBM.
View Article and Find Full Text PDFGastrointestinal Bleeding/Angiodysplasia in Patients With Glanzmann Thrombasthenia.
J Med Cases
December 2024
Madinah Hereditary Blood Disorders Centre, Department of Hematology and Oncology, King Salman Bin Abdulaziz Medical City, Madinah, Saudi Arabia.
Article Synopsis
- * A rare complication of GT is gastrointestinal angiodysplasia (GIAD), which involves abnormal blood vessel formation in the digestive system and has been documented in eight cases.
- * Treatment options for GIAD include surgical methods, electrocoagulation, and medications, but it has a high chance of recurring, as demonstrated in reported cases of patients with both GT and gastrointestinal bleeding.
Emerging immunologic approaches as cancer anti-angiogenic therapies.
Clin Transl Oncol
September 2024
Mass General Cancer Center, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Targeting tumor angiogenesis, the formation of new blood vessels supporting cancer growth and spread, has been an intense focus for therapy development. However, benefits from anti-angiogenic drugs like bevacizumab have been limited by resistance stemming from activation of compensatory pathways. Recent immunotherapy advances have sparked interest in novel immunologic approaches that can induce more durable vascular pruning and overcome limitations of existing angiogenesis inhibitors.
View Article and Find Full Text PDFRecent advances in the treatment of refractory gastrointestinal angiodysplasia.
United European Gastroenterol J
October 2024
Sorbonne University, Center for Digestive Endoscopy, Saint Antoine Hospital, AP HP, Paris, France.
Article Synopsis
- - Gastrointestinal angiodysplasia (GIA) is a prevalent, acquired vascular issue in the digestive tract, often leading to significant bleeding and requiring repeat treatments such as transfusions or endoscopies.
- - Recent studies focus on non-endoscopic options for treating refractory GIA, highlighting the effectiveness of aortic valve replacement in cases of Heyde syndrome and the use of anti-angiogenic drugs like Octreotide and Thalidomide.
- - Future advancements in understanding the underlying mechanisms of GIA could pave the way for the development of new, targeted treatments.
Understanding hereditary hemorrhagic telangiectasia: From genetic anomalies to systemic manifestations, quality of life, and epistaxis management-Exploring the otolaryngologist's integral role.
Auris Nasus Larynx
April 2024
Department of Otorhinolaryngology-Head and Neck Surgery, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan.
Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Rendu-Weber syndrome, is a rare autosomal dominant disorder characterized by vascular malformations. This comprehensive review aimed to provide an overview and summarize various aspects of HHT, including the genetic abnormalities, complications associated with visceral arteriovenous malformations (AVMs), prognosis of HHT, quality of life (QOL), and treatment of epistaxis. In addition, this review highlights the challenges in diagnosing HHT and emphasizes the critical role of otolaryngologists in the early detection of HHT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!